Correction to: Prevalence of tumour-infiltrating CD103<sup>+</sup> cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.

Correction to: Prevalence of tumour-infiltrating CD103⁺ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome.

Zhou, Quan; Ou, Yuxi; Dai, Xiyu; Chen, Xinan; Wu, Siqi; Chen, Wensun; Hu, Mengbo; Yang, Chen; Zhang, Limin; Jiang, Haowen.

Afiliação

Zhou Q; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Ou Y; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Dai X; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Chen X; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Wu S; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Chen W; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Hu M; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Yang C; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Zhang L; Department of Urology, Huashan Hospital, Fudan University, Shanghai, China.
Jiang H; Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China.

Br J Cancer ; 128(9): 1788-1789, 2023 May.

Article em En | MEDLINE | ID: mdl-36941407

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article